Opexa Therapeutics (OPXA)
Opexa Therapeutics Revenues
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these OPXA related companies
OPXA News
Opexa Therapeutics Reports First Quarter 2012 Financial Results and Provides Corporate Update
May 11, 8:30AM Business Wire
May 11, 8:30AM Business Wire
Will $OPXA go up on this news? (sorry about double post) http://stks.co/3TTH
about 38 days ago by drewbruckner
about 38 days ago by drewbruckner
Opexa to Hold Preliminary Investigator’s Meeting for MS Trial at American Academy of Neurology Annual Meeting
Apr 19, 8:30AM Business Wire
Apr 19, 8:30AM Business Wire
Opexa Therapeutics Reports Year End 2011 Financial Results and Provides Corporate Update
Feb 27, 8:29AM Business Wire
Feb 27, 8:29AM Business Wire
Opexa Therapeutics to Present at the 14th Annual BIO CEO & Investor Conference
Feb 08, 8:30AM Business Wire
Feb 08, 8:30AM Business Wire
Opexa Therapeutics to Present at the BOCEMb; Noble Financial Capital Markets’ Eighth Annual Equity Conference
Jan 17, 8:30AM Business Wire
Jan 17, 8:30AM Business Wire
Opexa Therapeutics to Present at the Oppenheimer 22nd Annual Healthcare Conference
Dec 09, 8:30AM Business Wire
Dec 09, 8:30AM Business Wire
Opexa Therapeutics to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
Nov 11, 8:30AM Business Wire
Nov 11, 8:30AM Business Wire
Opexa’s Tovaxin® for the Treatment of Multiple Sclerosis Granted Fast Track Designation by FDA
Nov 08, 8:30AM Business Wire
Nov 08, 8:30AM Business Wire
Opexa Therapeutics Reports Third Quarter 2011 Financial Results and Provides Corporate Update
Nov 04, 8:30AM Business Wire
Nov 04, 8:30AM Business Wire
$OPXA Getting ready for Phase3; How do I know: Hiring 5 more people. Bringing headcount from 13 to 18. Only one reason to add staff!
about 218 days ago by Sushifishman23
about 218 days ago by Sushifishman23
@SpreadCents $OPXAW r priced at $2.00. People buying 1 share of $OPXA for $.40 now, only to sell when $ is way above $2.40. Some 1 knows
about 218 days ago by Sushifishman23
about 218 days ago by Sushifishman23
$OPXA Just hit another 2500 at 1.13. Someone's got to help push up. News Thursday post shareholder meeting??
about 220 days ago by SpreadCents
about 220 days ago by SpreadCents
$OPXA I did, a little higher than I wanted to. Watched it around $1.06ish this morning but pulled the trigger at $1.09. And now we wait...
about 226 days ago by SpreadCents
about 226 days ago by SpreadCents
After pounding out of $ANDS today, I'm going to buy 5k in $OPXA tomorrow. Hopefully it'll hold the $1 line and start moving North.
about 227 days ago by SpreadCents
about 227 days ago by SpreadCents
Opexa to Present at the Rodman & Renshaw Annual Global Investment Conference - Healthcare on September 13, 2011
Sep 07, 8:30AM Business Wire
Sep 07, 8:30AM Business Wire
unusually high volume on $OPXA. already half of daily average. looking to break out after long setup last week or so.
about 281 days ago by ishamkhan
about 281 days ago by ishamkhan
$OPXA bounced nicely off 1.40, let's see where it can go. I say 2.25 in 2 mths. lots of shorts, phase 3 trials.
about 290 days ago by ishamkhan
about 290 days ago by ishamkhan
Opexa Therapeutics Reports Second Quarter 2011 Financial Results and Provides Corporate Update
Aug 11, 8:30AM Business Wire
Aug 11, 8:30AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| OPXA | 0.4725 | +0.00 | +0.51% | 10.84M |
| OPWV | 2.92 | +0.00 | +0.00% | 250.48M |
| OPTT | 2.12 | -0.04 | -1.85% | 22.49M |
| OPTR | 14.95 | -0.18 | -1.19% | 707.33M |
| OPNT | 24.96 | -0.68 | -2.65% | 578.44M |
| OPLK | 12.81 | +0.14 | +1.10% | 243.52M |
| OPHC | 0.6402 | -0.02 | -3.29% | 14.65M |
| OPEN | 39.64 | +0.00 | +0.00% | 893.88M |